vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Sila Realty Trust, Inc. (SILA). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $50.1M, roughly 1.5× Sila Realty Trust, Inc.). On growth, Sila Realty Trust, Inc. posted the faster year-over-year revenue change (7.6% vs -36.9%). Over the past eight quarters, Sila Realty Trust, Inc.'s revenue compounded faster (-0.6% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Sila Realty Trust, Inc. is a U.S.-based real estate investment trust that owns, operates, and acquires high-quality income-generating commercial properties. Its core portfolio covers industrial logistics facilities, office assets and mixed-use properties, serving tenants across logistics, corporate and retail segments to deliver stable long-term returns.

MED vs SILA — Head-to-Head

Bigger by revenue
MED
MED
1.5× larger
MED
$75.1M
$50.1M
SILA
Growing faster (revenue YoY)
SILA
SILA
+44.5% gap
SILA
7.6%
-36.9%
MED
Faster 2-yr revenue CAGR
SILA
SILA
Annualised
SILA
-0.6%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
SILA
SILA
Revenue
$75.1M
$50.1M
Net Profit
$5.0M
Gross Margin
69.4%
88.9%
Operating Margin
-10.4%
Net Margin
10.0%
Revenue YoY
-36.9%
7.6%
Net Profit YoY
-54.9%
EPS (diluted)
$-1.64
$0.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
SILA
SILA
Q4 25
$75.1M
$50.1M
Q3 25
$89.4M
$49.8M
Q2 25
$105.6M
$48.7M
Q1 25
$115.7M
$48.3M
Q4 24
$119.0M
$46.5M
Q3 24
$140.2M
$46.1M
Q2 24
$168.6M
$43.6M
Q1 24
$174.7M
$50.6M
Net Profit
MED
MED
SILA
SILA
Q4 25
$5.0M
Q3 25
$-2.3M
$11.6M
Q2 25
$2.5M
$8.6M
Q1 25
$-772.0K
$7.9M
Q4 24
$11.1M
Q3 24
$1.1M
$11.9M
Q2 24
$-8.2M
$4.6M
Q1 24
$8.3M
$15.0M
Gross Margin
MED
MED
SILA
SILA
Q4 25
69.4%
88.9%
Q3 25
69.5%
88.1%
Q2 25
72.6%
87.7%
Q1 25
72.8%
86.9%
Q4 24
74.1%
87.3%
Q3 24
75.4%
87.4%
Q2 24
73.2%
86.6%
Q1 24
72.8%
89.0%
Operating Margin
MED
MED
SILA
SILA
Q4 25
-10.4%
Q3 25
-4.6%
Q2 25
-1.0%
Q1 25
-1.1%
Q4 24
0.6%
Q3 24
1.5%
Q2 24
-4.7%
Q1 24
4.5%
Net Margin
MED
MED
SILA
SILA
Q4 25
10.0%
Q3 25
-2.5%
23.3%
Q2 25
2.3%
17.6%
Q1 25
-0.7%
16.4%
Q4 24
23.9%
Q3 24
0.8%
25.9%
Q2 24
-4.8%
10.6%
Q1 24
4.8%
29.6%
EPS (diluted)
MED
MED
SILA
SILA
Q4 25
$-1.64
$0.10
Q3 25
$-0.21
$0.21
Q2 25
$0.22
$0.15
Q1 25
$-0.07
$0.14
Q4 24
$0.08
$0.20
Q3 24
$0.10
$0.21
Q2 24
$-0.75
$0.08
Q1 24
$0.76
$0.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
SILA
SILA
Cash + ST InvestmentsLiquidity on hand
$167.3M
$32.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$1.3B
Total Assets
$248.0M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
SILA
SILA
Q4 25
$167.3M
$32.3M
Q3 25
$173.5M
$27.7M
Q2 25
$162.7M
$24.8M
Q1 25
$164.6M
$30.5M
Q4 24
$162.3M
$39.8M
Q3 24
$170.0M
$28.6M
Q2 24
$163.5M
$87.0M
Q1 24
$156.4M
$90.2M
Stockholders' Equity
MED
MED
SILA
SILA
Q4 25
$198.9M
$1.3B
Q3 25
$214.7M
$1.3B
Q2 25
$216.0M
$1.4B
Q1 25
$211.0M
$1.4B
Q4 24
$210.1M
$1.4B
Q3 24
$207.3M
$1.4B
Q2 24
$205.3M
$1.5B
Q1 24
$211.0M
$1.5B
Total Assets
MED
MED
SILA
SILA
Q4 25
$248.0M
$2.1B
Q3 25
$268.2M
$2.1B
Q2 25
$269.3M
$2.0B
Q1 25
$280.0M
$2.0B
Q4 24
$284.2M
$2.0B
Q3 24
$291.2M
$2.0B
Q2 24
$293.5M
$2.1B
Q1 24
$302.8M
$2.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
SILA
SILA
Operating Cash FlowLast quarter
$-5.3M
$119.1M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
23.76×
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
SILA
SILA
Q4 25
$-5.3M
$119.1M
Q3 25
$12.1M
$30.0M
Q2 25
$-3.4M
$31.9M
Q1 25
$3.4M
$24.1M
Q4 24
$-4.9M
$132.8M
Q3 24
$9.1M
$29.1M
Q2 24
$13.1M
$31.6M
Q1 24
$7.3M
$36.6M
Free Cash Flow
MED
MED
SILA
SILA
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
MED
MED
SILA
SILA
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
MED
MED
SILA
SILA
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
MED
MED
SILA
SILA
Q4 25
23.76×
Q3 25
2.59×
Q2 25
-1.36×
3.71×
Q1 25
3.06×
Q4 24
11.95×
Q3 24
8.04×
2.43×
Q2 24
6.84×
Q1 24
0.88×
2.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons